Company’s 36-month beta value is 7.52.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VVOS is 3.84M, and currently, short sellers hold a 3.86% ratio of that floaft. The average trading volume of VVOS on December 26, 2024 was 206.55K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VVOS) stock’s latest price update
The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) has dropped by -6.05 compared to previous close of 5.12. Despite this, the company has seen a fall of -0.61% in its stock price over the last five trading days. proactiveinvestors.com reported 2024-12-23 that Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.5 million before expenses. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement.
VVOS’s Market Performance
VVOS’s stock has fallen by -0.61% in the past week, with a monthly rise of 52.19% and a quarterly rise of 50.31%. The volatility ratio for the week is 14.47% while the volatility levels for the last 30 days are 12.17% for Vivos Therapeutics Inc The simple moving average for the past 20 days is 11.19% for VVOS’s stock, with a 66.92% simple moving average for the past 200 days.
VVOS Trading at 40.59% from the 50-Day Moving Average
After a stumble in the market that brought VVOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.51% of loss for the given period.
Volatility was left at 12.17%, however, over the last 30 days, the volatility rate increased by 14.47%, as shares surge +42.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +95.53% upper at present.
During the last 5 trading sessions, VVOS fell by -1.84%, which changed the moving average for the period of 200-days by +0.94% in comparison to the 20-day moving average, which settled at $4.32. In addition, Vivos Therapeutics Inc saw -60.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VVOS
Current profitability levels for the company are sitting at:
- -0.85 for the present operating margin
- 0.6 for the gross margin
The net margin for Vivos Therapeutics Inc stands at -0.86. The total capital return value is set at -1.21. Equity return is now at value -325.98, with -97.94 for asset returns.
Currently, EBITDA for the company is -16.68 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 1.27. The receivables turnover for the company is 32.12for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.44.
Conclusion
In a nutshell, Vivos Therapeutics Inc (VVOS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
